The Washington Times
  • Subscribe
  • Times News Services
  • RSS
  • Mobile Headlines
  • e-edition
  • E-MAIL ALERTS
  • REGISTER
  • LOG IN
  • E-MAIL ALERTS
  • WELCOME
  • Your Profile
  • Log Out
  • Front Page Image
  • Classifieds
  • Autos
  • Real Estate
  • Jobs
  • Special Sections
  • Customer Service
  • Home
  • News
  • Opinion
  • Sports
    • NFL
    • NBA/WNBA
    • MLB
    • NHL
    • Tennis
    • Golf
    • Motorsports
    • Soccer
    • NCAA
    • Olympics
    • Outdoors
    • Other
  • Culture
    • Home & Living
    • Family & Kids
    • Fashion
    • Food
    • Travel
    • Health
    • Washington Visitors
    • Books
    • Military History
    • Life
    • Auto
    • TV Listings
    • Movie Listings
    • Death Notices
    • Entertainment
  • Themes
  • Communities
  • Shopping
    • Stores
    • Coupons
    • Daily Double
    • Promotion
    • How It Works
  • Videos
    • Two Guys
    • Birnbaum on Washington
    • Liz Glover
    • Amanda Carpenter
    • Morning Briefing
    • Documentaries
    • Joe Giganti
    • Video Game Minute
  • Podcasts
    • About Headlines
    • Audio and Radio
    • America's Morning News
  • Sports

    KNOTT: Pollin honored as a D.C. treasure

  • Sports

    Jamison lights fire under Wizards

  • Politics

    Uninvited White House guests met Obama in line

  • Sports

    Wife aids Woods after SUV crash

  • National

    Volunteers for drug trials hard to find

  • Business

    Dubai debt crisis rocks U.S., Asia markets

  • World

    Piracy threatens fishermen in Yemen

Monday, April 25, 2005

FDA in a pain-pill panic

Rate this story

Average 0.00
after 0 votes
Login or register to rate this story

  • Font Size -+
  • Print
  • Email
  • Comment
  • Tweet this!
  • Share
  • Article
  • Comments ()
  • Click-2-Listen
  • Videos

More Stories

  • Atlantis, crew of 7 back on Earth
  • Uninvited White House guests met Obama in line
  • iPhone lands in Korea
  • Wife aids Woods after SUV crash

By

The Food and Drug Administration just yanked or restricted all but two of the nation's top painkilling drugs, throwing patients requiring regular anesthesia into what Dr. Joshua Prager, head of the University of California-Los Angeles Pain Center, called "great confusion, not only among patients, but for physicians" about how to treat severe and chronic pain.

The only painkillers the FDA will recommend as working without long-term high-risk are aspirin and acetaminophen (Tylenol). Popular nonprescription drugs ibuprofen (Advil, Motrin, etc.) and naproxen (Aleve) will now require warnings against using more than two weeks. The prescription COX-2 inhibitor drug Bextra will be taken off the market and Celebrex (and Vioxx, if its manufacturer is willing to go back on the market) will require the maximum "black box" warning that its use could cause heart attacks and strokes.

Two days before the decision, Democratic Sens. Hillary Rodham Clinton of New York, Patty Murray of Washington and Edward Kennedy of Massachusetts confronted Dr. Lester M. Crawford, President Bush's choice for permanent FDA administrator, and placed his nomination on "indefinite hold."

Backed by the Ralph Naderite Public Citizen's Health Research Group, supported by trial lawyers and endorsed by many other liberal legislators, the senators' mission is to promote absolute safety via maximum political and bureaucratic regulation, unlimited access to health litigation against drug businesses and, ultimately, elimination of private medicine in favor of government-run health care.

Rule No. 1 for bureaucratic regulators is: What you do can get you in trouble with activists and politicians, what you deny no one can see. The ideal would be approving no drugs so no one could get hurt using them (nor blame the approving bureaucrat). The next best is to test them to death over the longest period possible in an effort to eliminate all risk.

Regulators, being statisticians, know it is impossible to eliminate all risk but can always rule on the side of caution. The only little problem is people die during the endless approval process. But no one can be sure they died from not having a drug not known to be available.

The FDA bias toward endless testing is most noticeable for patients with incurable diseases. The bureau insists experimental drugs for these patients must meet the tightest standards with thousands of patients tested under statistical methodology utilizing "blind" controlled experiments: Some patients receiving the full dose and some little or no dose at all.

Controlled experiments may make some sense for aspirin. But even the FDA should recognize the true control in terminal diseases is all patients will die if they get the sugar pill.

When a father started Abigail Alliance to save his little girls' life by proposing a new expedited procedure without many controlled tests (as done in early phase tests) for terminally ill patients with no other recourse, the bureaucrats denied the request and defended the existing system for its efficiency, specifically mentioning the colon cancer drug Eloxatin.

Eloxatin was FDA-accelerated but not endorsed until 2003, by which time 56 nations had already approved it. France, the epitome of rigid bureaucracy, approved it 1996, saving colon cancer lives for the seven years it was unavailable in the U.S. Someone very dear to me was recently diagnosed with melanoma. While it is presently under control, she is refused vaccines stalled in clinical tests for years.

12Next »

Post a comment

There are comments on this article, submit your opinion!

Commenting is disabled for this entry.
If you feel there is still something worth mentioning about this entry please contact the author or the site admin.

Ask a Question

You Report

Do you have another point of view, photos, audio, video or more information about a story?

Top Stories

Most Read

  1. EDITORIAL: Hiding evidence of global cooling
  2. Climate 'czar' says hacked e-mails don't change anything
  3. EDITORIAL: The global-cooling cover-up
  4. Wife aids Woods after SUV crash
  5. PRUDEN: Trouble afoot for high priests
More Top Stories »
  1. In tobacco-loving Virginia, bars give up the habit
  2. Grade-schooler unearths fossil at dinosaur park
  3. Climate czar rejects doctored data claims
  4. HOLMES: Behind Obama's overseas allure
  5. EDITORIAL: The duty of a nation to obey God

Most Shared

  1. EDITORIAL: The global-cooling cover-up
  2. PRUDEN: Trouble afoot for high priests
  3. EDITORIAL: Hiding evidence of global cooling
  4. Climate 'czar' says hacked e-mails don't change anything
  5. Finance mavens gloomy
More Top Stories »
  1. In tobacco-loving Virginia, bars give up the habit
  2. Fenty's approval in D.C. divided by race
  3. Drug lords finding safe haven in Bolivia
  4. Global Warmists exposed
  5. EDITORIAL: The duty of a nation to obey God

Most Commented

  1. Climate 'czar' says hacked e-mails don't change anything
  2. EDITORIAL: The global-cooling cover-up
  3. Climate czar rejects doctored data claims
  4. PRUDEN: Trouble afoot for high priests
  5. EDITORIAL: Hiding evidence of global cooling
More Top Stories »
  1. EDITORIAL: The duty of a nation to obey God
  2. Crashers probe may become criminal investigation
  3. HOLMES: Behind Obama's overseas allure
  4. Obama taking emissions goal to summit
  5. 9/11 families sharply split on civilian court trials

Listen to Washington Times Radio

  • America's Morning News

    with John McCaslin and Melanie Morgan

Blogs & Columns

  • Hot Button Blog

    RNC: Breast cancer recommendations may lead to 'rationing'

  • Belief Blog

    Evangelicals OK civil disobedience

  • Out of Context

    Foods that might kill libido

  • On the Fly

    United lifts some 'award' blocking

  • Technology

    Facebook wins round against phishing spammer

  • Redskins 360

    Hall out, Rogers will start

  • SNOBlog

    Beyond 'Woody'

Videos

Advertising Links
TWT Store
  • e-edition
  • Print Edition
  • Weekly Washington Times
TWT Affiliates
  • Middle East Times
  • Golf
  • UPI
  • Arbor Ballroom
  • Washington Times Global
  • About TWT
  • Press Room
  • F.A.Q.
  • Work for TWT
  • Advertise
  • Sponsors
  • Contact Us
  • Privacy Policy
  • Site Map

All site contents © Copyright 2009 The Washington Times, LLC.